

C Michael Gibson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4721299/c-michael-gibson-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|--------------------|--------------------------|----------------|-----------------|
| 595 papers | 50,330 citations | 101 h-index | 215 g-index |
| 690 ext. papers | 58,559 ext. citations | 8.3 avg, IF | 6.97 L-index |

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 595 | Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy.. <i>JACC: Cardiovascular Interventions</i> , 2022 , 15, 282-282 | 5 | 0 |
| 594 | Early and late recurrent cardiovascular events among high-risk patients with an acute coronary syndrome: Meta-analysis of phase III studies and implications on trial design.. <i>Clinical Cardiology</i> , 2022 , | 3.3 | 2 |
| 593 | Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial.. <i>Thrombosis Research</i> , 2022 , 211, 63-69 | 8.2 | |
| 592 | Worldwide differences of hospitalization for ST-segment elevation myocardial infarction during COVID-19: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2022 , 347, 89-96 | 3.2 | 6 |
| 591 | Evolution of single-lead ECG for STEMI detection using a deep learning approach. <i>International Journal of Cardiology</i> , 2022 , 346, 47-52 | 3.2 | 1 |
| 590 | Independence of Clinical Events Committees: A Consensus Statement from Clinical Research Organizations.. <i>American Heart Journal</i> , 2022 , 248, 120-120 | 4.9 | 0 |
| 589 | Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity.. <i>Journal of the American Heart Association</i> , 2022 , e024754 | 6 | 0 |
| 588 | Digital technologies and the democratization of clinical research: Social media, wearables, and artificial intelligence.. <i>Contemporary Clinical Trials</i> , 2022 , 106767 | 2.3 | 0 |
| 587 | Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 1660-1671 | 15.1 | 7 |
| 586 | Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.. <i>Circulation: Cardiovascular Interventions</i> , 2021 , CIRCINTERVENTIONS120010390 | 6 | 0 |
| 585 | Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. <i>Circulation</i> , 2021 , 143, 479-500 | 16.7 | 34 |
| 584 | Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings from the EXTEND-DAPT Study. <i>Circulation</i> , 2021 , | 16.7 | 4 |
| 583 | Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.. <i>European Heart Journal</i> , 2021 , | 9.5 | 8 |
| 582 | Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1525-1537 | 15.1 | 6 |
| 581 | Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. <i>Circulation</i> , 2021 , 144, 1845-1855 | 16.7 | 10 |
| 580 | The multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, e29-e30 | 6.4 | |
| 579 | Prognosis of Claims- Versus Trial-Based Ischemic and Bleeding Events Beyond 1 Year After Coronary Stenting. <i>Journal of the American Heart Association</i> , 2021 , 10, e018744 | 6 | 1 |

| | | | |
|-----|--|------|-----|
| 578 | Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 1562-1573 | 7 | 1 |
| 577 | Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults. <i>PLoS ONE</i> , 2021 , 16, e0251963 | 3.7 | 23 |
| 576 | Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective. <i>American Journal of Cardiovascular Drugs</i> , 2021 , 1 | 4 | 1 |
| 575 | Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses. <i>Circulation</i> , 2021 , 143, 33-44 | 16.7 | 25 |
| 574 | Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. <i>American Heart Journal</i> , 2021 , 231, 124-127 | 4.9 | 16 |
| 573 | Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 550-558 | 6.4 | 14 |
| 572 | Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 254-264 | 27.4 | 157 |
| 571 | Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 444-456 | 5 | 3 |
| 570 | Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. <i>Circulation</i> , 2021 , 143, 685-695 | 16.7 | 3 |
| 569 | Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update. <i>Circulation</i> , 2021 , 143, 583-596 | 16.7 | 31 |
| 568 | Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 1434-1446 | 5 | 1 |
| 567 | Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials. <i>Journal of Medical Virology</i> , 2021 , 93, 6737-6749 | 19.7 | 4 |
| 566 | Bleeding avoidance strategies in percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2021 , | 14.8 | 10 |
| 565 | Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. <i>European Heart Journal</i> , 2021 , 42, 4683-4693 | 9.5 | 5 |
| 564 | Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 1032-1041 | 16.2 | 8 |
| 563 | Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , | 6.4 | 14 |
| 562 | Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review. <i>Journal of the American Heart Association</i> , 2020 , 9, e018897 | 6 | 9 |
| 561 | VE-1902-A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis. <i>Thrombosis Research</i> , 2020 , 190, 112-121 | 8.2 | 4 |

| | | | |
|-----|--|------|-----|
| 560 | Echocardiographic assessment of insulin-like growth factor binding protein-7 and early identification of acute heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 1664-1675 | 3.7 | 6 |
| 559 | Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial. <i>American Heart Journal</i> , 2020 , 226, 49-59 | 4.9 | 87 |
| 558 | Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1004-1024 | 7 | 147 |
| 557 | Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 924-936 | 7 | 5 |
| 556 | Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry. <i>Circulation: Cardiovascular Interventions</i> , 2020 , 13, e008226 | 6 | 9 |
| 555 | Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2020 , 195, 128-135 | 8.2 | 1 |
| 554 | Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis. <i>JAMA Cardiology</i> , 2020 , 5, 582-589 | 16.2 | 34 |
| 553 | Machine learning to predict venous thrombosis in acutely ill medical patients. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 230-237 | 5.1 | 15 |
| 552 | Patients with acute and chronic coronary syndromes have elevated long-term thrombin generation. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 50, 421-429 | 5.1 | 0 |
| 551 | Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 578-586 | 15.1 | 39 |
| 550 | Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020 , 17, 242-257 | 14.8 | 41 |
| 549 | Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2403-2413 | 15.1 | 34 |
| 548 | Ticagrelor With or Without Aspirin After Complex PCI. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2414-2424 | 15.1 | 58 |
| 547 | Dynamic Coronary Angiography and Flow 2020 , 29-72 | | |
| 546 | Ostial Lesions 2020 , 310-330 | | |
| 545 | Balloon Angioplasty 2020 , 125-139 | | |
| 544 | Coronary Atherectomy 2020 , 486-504 | | |
| 543 | Infrainguinal and Infragenicular Interventions 2020 , 603-623 | | |

542 Bifurcation Lesion **2020**, 388-419

541 MitraClip[Mitral Valve Repair System **2020**, 639-651

540 Interventions in Patients after Coronary Artery Bypass Graft **2020**, 364-387

539 Carotid Artery Occlusive Disease **2020**, 553-579

538 Subclavian Artery Interventions **2020**, 523-538

537 Bioresorbable Vascular Scaffolds **2020**, 167-185

536 Watchman[Left Atrial Appendage Closure Device **2020**, 701-713

535 High-risk Patients **2020**, 467-485

534 Chronic Total Occlusion **2020**, 257-309

533 Left Main Percutaneous Coronary Intervention **2020**, 239-256

532 Retrograde Percutaneous Aortic Valvuloplasty **2020**, 690-700

531 Renal Artery Interventions **2020**, 539-552

530 Interventions in Acute Ischemic Stroke **2020**, 714-737

529 Guides **2020**, 73-108

528 Stenting **2020**, 140-166

527 Slender Transradial Intervention **2020**, 225-238

526 Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. *Seminars in Thrombosis and Hemostasis*, **2020**, 46, 908-918 5.3 4

525 A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. *Catheterization and Cardiovascular Interventions*, **2020**, 96, E102-E109 2.7 4

| | | | |
|-----|--|------|------|
| 524 | REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States. <i>Circulation</i> , 2020 , 141, 367-375 | 16.7 | 67 |
| 523 | Procedural, clinical, and health status outcomes in chronic total coronary occlusion revascularization: Results from the PERSPECTIVE study. <i>Catheterization and Cardiovascular Interventions</i> , 2020 , 96, 567-576 | 2.7 | 4 |
| 522 | The AngelMed Guardian System in the Detection of Coronary Artery Occlusion: Current Perspectives. <i>Medical Devices: Evidence and Research</i> , 2020 , 13, 1-12 | 1.5 | 1 |
| 521 | Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients With Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial). <i>American Journal of Cardiology</i> , 2020 , 125, 661-669 | 3 | 2 |
| 520 | Feasibility and Safety of Low-Dose Intra-Coronary Tenecteplase During Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (ICE T-TIMI 49). <i>American Journal of Cardiology</i> , 2020 , 125, 485-490 | 3 | 6 |
| 519 | Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020 , 41, 3533-3545 | 9.5 | 37 |
| 518 | Outcomes following revascularization with radial artery bypass grafts: Insights from the PREVENT-IV trial. <i>American Heart Journal</i> , 2020 , 228, 91-97 | 4.9 | |
| 517 | Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study. <i>Circulation</i> , 2020 , 142, 306-308 | 16.7 | 3 |
| 516 | Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2020 , 9, e017212 | 6 | 24 |
| 515 | Randomized Trials Versus Common Sense and Clinical Observation: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 580-589 | 15.1 | 22 |
| 514 | First Human Use of RUC-4: A Nonactivating Second-Generation Small-Molecule Platelet Glycoprotein IIb/IIIa (Integrin $\alpha_{IIb}\beta_3$) Inhibitor Designed for Subcutaneous Point-of-Care Treatment of ST-Segment-Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2020 , 9, e016552 | 6 | 7 |
| 513 | Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1468-1483 | 15.1 | 16 |
| 512 | Spontaneous coronary artery dissection and its association with takotsubo syndrome: Novel insights from a tertiary center registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020 , 95, 485-491 | 2.7 | 21 |
| 511 | Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 49, 1-9 | 5.1 | 21 |
| 510 | Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 49, 214-219 | 5.1 | 4 |
| 509 | Saphenous vein grafts in contemporary coronary artery bypass graft surgery. <i>Nature Reviews Cardiology</i> , 2020 , 17, 155-169 | 14.8 | 58 |
| 508 | COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2950-2973 | 15.1 | 1682 |
| 507 | Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , 2019 , 381, 2032-2042 | 59.2 | 395 |

| | | | |
|-----|--|------|-----|
| 506 | Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e007124 | 6 | 8 |
| 505 | Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials. <i>JAMA Cardiology</i> , 2019 , 4, 747-755 | 16.2 | 130 |
| 504 | ST-segment elevation myocardial infarction. <i>Nature Reviews Disease Primers</i> , 2019 , 5, 39 | 51.1 | 78 |
| 503 | P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019 , 4, 680-684 | 16.2 | 7 |
| 502 | Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , 2019 , 40, 2632-2653 | 9.5 | 169 |
| 501 | Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2019 , 140, 240-261 | 16.7 | 183 |
| 500 | Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 983-992 | 5 | 6 |
| 499 | Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial. <i>TH Open</i> , 2019 , 3, e103-e108 | 2.7 | 1 |
| 498 | Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e007133 | 6 | 10 |
| 497 | Risk Factors, Imaging Findings, and Sex Differences in Spontaneous Coronary Artery Dissection. <i>American Journal of Cardiology</i> , 2019 , 123, 1783-1787 | 3 | 34 |
| 496 | Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y Inhibitor Pretreatment. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e007445 | 6 | |
| 495 | Implantable Cardiac Alert System for Early Recognition of ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1919-1927 | 15.1 | 17 |
| 494 | Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post-Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS-TIMI 46 and ATLAS ACS 2-TIMI 51. <i>Journal of the American Heart Association</i> , 2019 , 8, | 6 | 2 |
| 493 | Most Promising Therapies in Interventional Cardiology. <i>Current Cardiology Reports</i> , 2019 , 21, 26 | 4.2 | 3 |
| 492 | Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2019 , 380, 1326-1335 | 59.2 | 431 |
| 491 | Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e007342 | 6 | 5 |
| 490 | Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 2089-2098 | 15.4 | 4 |
| 489 | Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1704-1711 | 7 | 2 |

| | | | |
|-----|---|------|-----|
| 488 | The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. <i>Clinical Cardiology</i> , 2019 , 42, 797 | 3.3 | 2 |
| 487 | Logistical Challenges Associated With Implementing Precision Medicine-Reply. <i>JAMA Cardiology</i> , 2019 , 4, 1301 | 16.2 | 1 |
| 486 | Implanted Monitor Alerting to Reduce Treatment Delay in Patients With Acute Coronary Syndrome Events. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2047-2055 | 15.1 | 8 |
| 485 | Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. <i>Circulation</i> , 2019 , 139, 1234-1236 | 16.7 | 4 |
| 484 | Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. <i>Intensive Care Medicine</i> , 2019 , 45, 477-487 | 14.5 | 12 |
| 483 | Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e008160 | 6 | 0 |
| 482 | Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 3013-3022 | 15.1 | 30 |
| 481 | Comparison of Outcomes and Frequency of Graft Failure With Use of Free Versus In Situ Internal Mammary Artery Bypass Conduits (from the PREVENT IV Trial). <i>American Journal of Cardiology</i> , 2019 , 123, 571-575 | 3 | 4 |
| 480 | Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis). <i>American Journal of Cardiology</i> , 2019 , 123, 355-360 | 3 | 5 |
| 479 | The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. <i>American Heart Journal</i> , 2019 , 208, 81-90 | 4.9 | 16 |
| 478 | Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. <i>International Journal of Cardiology</i> , 2019 , 278, 217-222 | 3.2 | 3 |
| 477 | Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e004945 | 5.8 | 3 |
| 476 | Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. <i>American Journal of Hematology</i> , 2019 , 94, 21-28 | 7.1 | 28 |
| 475 | Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 186-193 | 4.3 | 9 |
| 474 | The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 695-702 | 4.3 | 8 |
| 473 | Effect of Cocaine on Coronary Microvasculature. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 954-955 | 15.1 | 2 |
| 472 | 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Circulation</i> , 2018 , 137, 961-972 | 16.7 | 175 |
| 471 | Rivaroxaban and Post-Stroke Neurological Outcomes in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1048-1049 | 15.1 | 3 |

| | | | |
|-----|--|------|-----|
| 470 | 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1021-1034 | 15.1 | 122 |
| 469 | Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. <i>American Journal of Medicine</i> , 2018 , 131, 972.e1-972.e7 | 2.4 | 15 |
| 468 | Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). <i>Circulation: Cardiovascular Interventions</i> , 2018 , 11, e005635 | 6 | 9 |
| 467 | Dual (Anticoagulant Plus Single Antiplatelet) vs Triple (Anticoagulant Plus Dual Antiplatelet) Antithrombotic Therapy - "Real World" Experience. <i>Progress in Cardiovascular Diseases</i> , 2018 , 60, 531-536 | 8.5 | 5 |
| 466 | Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Progress in Cardiovascular Diseases</i> , 2018 , 60, 524-530 | 8.5 | 4 |
| 465 | Uremic Solute-Aryl Hydrocarbon Receptor-Tissue Factor Axis Associates with Thrombosis after Vascular Injury in Humans. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 1063-1072 | 12.7 | 57 |
| 464 | Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial). <i>Circulation</i> , 2018 , 137, 91-94 | 16.7 | 25 |
| 463 | Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. <i>American Heart Journal</i> , 2018 , 198, 84-90 | 4.9 | 16 |
| 462 | Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study. <i>Catheterization and Cardiovascular Interventions</i> , 2018 , 92, E348-E355 | 2.7 | 5 |
| 461 | Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients). <i>Circulation: Cardiovascular Interventions</i> , 2018 , 11, e005111 | 6 | 15 |
| 460 | Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 626-634 | 5 | 19 |
| 459 | Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018 , 7, 158-165 | 4.3 | 6 |
| 458 | Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. <i>American Heart Journal</i> , 2018 , 197, 1-8 | 4.9 | 5 |
| 457 | Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials. <i>International Journal of Cardiology</i> , 2018 , 250, 49-55 | 3.2 | 4 |
| 456 | Correlates and prognostic impact of new-onset heart failure after ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: insights from the INFUSE-AMI trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018 , 7, 339-347 | 4.3 | 13 |
| 455 | Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial. <i>TH Open</i> , 2018 , 2, e16-e24 | 2.7 | 6 |
| 454 | Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update. <i>Circulation</i> , 2018 , 138, 527-536 | 16.7 | 164 |
| 453 | Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials. <i>Atherosclerosis</i> , 2018 , 277, 211-218 | 3.1 | 9 |

| | | | |
|-----|---|------|-----|
| 452 | Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 856-864 | 5 | 16 |
| 451 | Reply: In Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention, One Size Cannot Fit All. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 1539-1540 | 5 | |
| 450 | D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy). <i>American Journal of Cardiology</i> , 2018 , 122, 1459-1464 | 3 | 13 |
| 449 | Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial. <i>American Heart Journal</i> , 2018 , 203, 17-24 | 4.9 | 9 |
| 448 | Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. <i>International Journal of Cardiology</i> , 2018 , 270, 96-101 | 3.2 | 7 |
| 447 | Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 45, 1-8 | 5.1 | 14 |
| 446 | Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 2046-2052 | 7 | 28 |
| 445 | Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial). <i>American Journal of Cardiology</i> , 2018 , 122, 1896-1901 | 3 | 12 |
| 444 | Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism. <i>Expert Review of Cardiovascular Therapy</i> , 2018 , 16, 845-855 | 2.5 | 4 |
| 443 | CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 997-1005 | 5.9 | 13 |
| 442 | Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. <i>European Heart Journal</i> , 2018 , 39, 3810-3820 | 9.5 | 18 |
| 441 | Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial. <i>European Heart Journal</i> , 2018 , 39, 4112-4120 | 9.5 | 32 |
| 440 | Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 46, 346-350 | 5.1 | 8 |
| 439 | Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 129-136 | 15.1 | 7 |
| 438 | Moving From Hope to Hard Work in Data Sharing. <i>JAMA Cardiology</i> , 2018 , 3, 795-796 | 16.2 | 2 |
| 437 | Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , 2018 , 15, 480-496 | 14.8 | 134 |
| 436 | Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 176-185 | 15.1 | 36 |
| 435 | Prevention of Bleeding in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2017 , 376, 994 | 59.2 | 1 |

| | | | |
|-----|---|------|-----|
| 434 | Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI: A Secondary Analysis of the HORIZONS-AMI Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2017 , 2, 673-677 | 16.2 | 4 |
| 433 | Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. <i>International Journal of Cardiology</i> , 2017 , 218, 133-139 | 3.2 | 8 |
| 432 | Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. <i>JAMA Cardiology</i> , 2017 , 2, 127-135 | 16.2 | 30 |
| 431 | Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials. <i>International Journal of Cardiology</i> , 2017 , 244, 59-66 | 3.2 | 16 |
| 430 | Evacetrapi and Cardiovascular Outcomes in High-Risk Vascular Disease. <i>New England Journal of Medicine</i> , 2017 , 376, 1933-1942 | 59.2 | 406 |
| 429 | Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. <i>American Heart Journal</i> , 2017 , 188, 147-155 | 4.9 | 2 |
| 428 | Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. <i>International Journal of Cardiology</i> , 2017 , 241, 87-96 | 3.2 | 16 |
| 427 | Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. <i>Lancet, The</i> , 2017 , 389, 1799-1808 | 40 | 132 |
| 426 | Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors. <i>Expert Review of Cardiovascular Therapy</i> , 2017 , 15, 237-245 | 2.5 | 10 |
| 425 | The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. <i>American Heart Journal</i> , 2017 , 185, 93-100 | 4.9 | 43 |
| 424 | Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2017 , 10, | 6 | 6 |
| 423 | The Democratization of Medical Research and Education Through Social Media: The Potential and the Peril. <i>JAMA Cardiology</i> , 2017 , 2, 9-11 | 16.2 | 6 |
| 422 | Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy. <i>Pharmaceutical Statistics</i> , 2017 , 16, 445-450 | 1 | 6 |
| 421 | N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 44, 457-465 | 5.1 | 8 |
| 420 | White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). <i>Circulation: Cardiovascular Interventions</i> , 2017 , 10, | 6 | 15 |
| 419 | Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX). <i>American Journal of Cardiology</i> , 2017 , 120, 1043-1048 | 3 | 9 |
| 418 | Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. <i>Journal of the American Heart Association</i> , 2017 , 6, | 6 | 30 |
| 417 | Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2017 , 15, 1913-1922 | 15.4 | 16 |

| | | | |
|-----|---|------|-----|
| 416 | Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX. <i>Circulation: Cardiovascular Interventions</i> , 2017 , 10, | 6 | 6 |
| 415 | The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. <i>TH Open</i> , 2017 , 1, e56-e65 | 2.7 | 62 |
| 414 | Response by Gibson and Fox to Letter Regarding Article, "Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy". <i>Circulation</i> , 2017 , 136, 117 | 16.7 | |
| 413 | Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry). <i>American Journal of Cardiology</i> , 2017 , 120, 904-910 | 3 | 7 |
| 412 | Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. <i>Circulation</i> , 2017 , 135, 323-333 | 16.7 | 72 |
| 411 | Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). <i>Circulation</i> , 2017 , 135, 648-655 | 16.7 | 46 |
| 410 | Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 89, E217-E225 | 2.7 | 10 |
| 409 | Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1093-1100 | 7 | 6 |
| 408 | Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 2389-2395 | 7 | 18 |
| 407 | Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016 , 21, 227-32 | 2.6 | 9 |
| 406 | Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2016 , 375, 1131-41 | 59.2 | 580 |
| 405 | Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. <i>American Heart Journal</i> , 2017 , 180, 22-30 | 4.9 | 23 |
| 404 | Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial). <i>American Journal of Cardiology</i> , 2016 , 118, 625-31 | 3 | 6 |
| 403 | A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. <i>American Heart Journal</i> , 2016 , 181, 92-100 | 4.9 | 17 |
| 402 | Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1905-13 | 5 | 27 |
| 401 | Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1461-9 | 5 | 27 |
| 400 | Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. <i>New England Journal of Medicine</i> , 2016 , 375, 2423-2434 | 59.2 | 929 |
| 399 | Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9, | 6 | 9 |

| | | | |
|-----|--|------|-----|
| 398 | Response to Letters Regarding Article, "Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial". <i>Circulation</i> , 2016 , 133, e665 | 16.7 | 0 |
| 397 | Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2016 , 87, 391-400 | 2.7 | 7 |
| 396 | Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial. <i>Circulation</i> , 2016 , 133, 248-55 | 16.7 | 23 |
| 395 | Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. <i>Circulation</i> , 2016 , 133, 131-8 | 16.7 | 51 |
| 394 | High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2016 , 171, 25-32 | 4.9 | 10 |
| 393 | A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. <i>American Heart Journal</i> , 2016 , 174, 120-8 | 4.9 | 22 |
| 392 | Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 596-8 | 15.1 | 20 |
| 391 | EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. <i>European Heart Journal</i> , 2016 , 37, 1296-303 | 9.5 | 87 |
| 390 | The treatment of missing data in a large cardiovascular clinical outcomes study. <i>Clinical Trials</i> , 2016 , 13, 344-51 | 2.2 | 9 |
| 389 | The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. <i>European Heart Journal</i> , 2016 , 37, 1122-30 | 9.5 | 20 |
| 388 | The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention with Extended Duration Betrixaban (APEX) Trial. <i>Blood</i> , 2016 , 128, 3824-3824 | 2.2 | |
| 387 | Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database. <i>Catheterization and Cardiovascular Interventions</i> , 2016 , 87, 363-73 | 2.7 | 6 |
| 386 | Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1349-57 | 5 | 36 |
| 385 | A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?. <i>Circulation</i> , 2016 , 134, 1881-1906 | 16.7 | 53 |
| 384 | Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). <i>Circulation</i> , 2016 , 134, 1918-1930 | 16.7 | 110 |
| 383 | Andexanet Alfa for Factor Xa Inhibitor Reversal. <i>New England Journal of Medicine</i> , 2016 , 375, 2499-500 | 59.2 | 19 |
| 382 | Betrixaban in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2016 , 375, e50 | 59.2 | 2 |
| 381 | Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2016 , 375, 534-44 | 59.2 | 286 |

| | | | |
|-----|---|------|-----|
| 380 | Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2224-2234 | 15.1 | 306 |
| 379 | Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9, e003114 | 6 | 12 |
| 378 | "Off-Hours" Versus "On-Hours" Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2385-2387 | 15.1 | 5 |
| 377 | Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. <i>American Heart Journal</i> , 2016 , 182, 125-134 | 4.9 | 84 |
| 376 | Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). <i>Circulation</i> , 2016 , 134, 723-33 | 16.7 | 23 |
| 375 | Effect of Smoking on Infarct Size and Major Adverse Cardiac Events in Patients With Large Anterior ST-Elevation Myocardial Infarction (from the INFUSE-AMI Trial). <i>American Journal of Cardiology</i> , 2016 , 118, 1097-1104 | 3 | 14 |
| 374 | Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 715-23 | 15.1 | 61 |
| 373 | A Living Systematic Review of Nebulized Hypertonic Saline for Acute Bronchiolitis in Infants. <i>JAMA Pediatrics</i> , 2015 , 169, 788-9 | 8.3 | 31 |
| 372 | Impact of time from symptom onset to drug administration on outcome in patients undergoing glycoprotein IIb/IIIa facilitated primary angioplasty (from the EGYPT cooperation). <i>American Journal of Cardiology</i> , 2015 , 115, 711-5 | 3 | 10 |
| 371 | Usefulness of the Left Anterior Descending Artery Wrapping Around the Left Ventricular Apex to Predict Adverse Clinical Outcomes in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction (an INFUSE-AMI Substudy). <i>American Journal of Cardiology</i> , 2015 , 115, 1389-95 | 3 | 15 |
| 370 | Dual Pathway Therapy for Secondary Prevention Following Acute Coronary Syndrome. <i>Current Cardiovascular Risk Reports</i> , 2015 , 9, 1 | 0.9 | |
| 369 | Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 484-488 | 5 | 27 |
| 368 | The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015 , 4, 468-74 | 4.3 | 15 |
| 367 | Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. <i>American Heart Journal</i> , 2015 , 170, 1061-9 | 4.9 | 63 |
| 366 | A randomized, double-blind, placebo-controlled trial to evaluate the safety and effectiveness of intracoronary application of a novel bioabsorbable cardiac matrix for the prevention of ventricular remodeling after large ST-segment elevation myocardial infarction: Rationale and design of the PRESERVATION I trial. <i>American Heart Journal</i> , 2015 , 170, 929-37 | 4.9 | 29 |
| 365 | Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 40, 317-22 | 5.1 | 23 |
| 364 | Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: results from the Project of Ex-vivo Vein Graft Engineering via Transfection IV trial. <i>American Heart Journal</i> , 2015 , 169, 175-84 | 4.9 | 16 |
| 363 | D-Dimer elevation and adverse outcomes. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 39, 55-9 | 5.1 | 45 |

| | | | |
|-----|---|------|-----|
| 362 | Predictive value of admission platelet volume indices for in-hospital major adverse cardiovascular events in acute ST-segment elevation myocardial infarction. <i>Angiology</i> , 2015 , 66, 155-62 | 2.1 | 51 |
| 361 | Sex, adverse cardiac events, and infarct size in anterior myocardial infarction: an analysis of intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction (INFUSE-AMI). <i>American Heart Journal</i> , 2015 , 169, 86-93 | 4.9 | 11 |
| 360 | Novel oral anticoagulants and reversal agents: Considerations for clinical development. <i>American Heart Journal</i> , 2015 , 169, 751-7 | 4.9 | 62 |
| 359 | Response to Letters Regarding Article, "Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery: Insights From PREVENT IV". <i>Circulation</i> , 2015 , 132, e29 | 16.7 | 3 |
| 358 | Utility of peak creatine kinase-MB measurements in predicting myocardial infarct size, left ventricular dysfunction, and outcome after first anterior wall acute myocardial infarction (from the INFUSE-AMI trial). <i>American Journal of Cardiology</i> , 2015 , 115, 563-70 | 3 | 44 |
| 357 | An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). <i>American Heart Journal</i> , 2015 , 169, 478-85 | 4.9 | 114 |
| 356 | Outcomes in diabetic patients undergoing primary percutaneous coronary intervention for acute anterior myocardial infarction: results from the INFUSE-AMI study. <i>Catheterization and Cardiovascular Interventions</i> , 2014 , 83, 704-10 | 2.7 | 16 |
| 355 | Clinical features, use of evidence-based therapies, and cardiovascular outcomes among patients with chronic kidney disease following non-ST-elevation acute coronary syndrome. <i>Clinical Cardiology</i> , 2014 , 37, 350-6 | 3.3 | 10 |
| 354 | Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. <i>Circulation</i> , 2014 , 130, 484-95 | 16.7 | 554 |
| 353 | Impact of delay to reperfusion on reperfusion success, infarct size, and clinical outcomes in patients with ST-segment elevation myocardial infarction: the INFUSE-AMI Trial (INFUSE-Anterior Myocardial Infarction). <i>JACC: Cardiovascular Interventions</i> , 2014 , 7, 733-40 | 5 | 38 |
| 352 | Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV. <i>Circulation</i> , 2014 , 130, 1445-51 | 16.7 | 138 |
| 351 | Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). <i>American Journal of Cardiology</i> , 2014 , 113, 1297-305 | 3 | 8 |
| 350 | Significance of left ventricular apical-basal muscle bundle identified by cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2014 , 35, 2706-13 | 9.5 | 39 |
| 349 | A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. <i>JACC: Cardiovascular Interventions</i> , 2014 , 7, 857-67 | 5 | 168 |
| 348 | Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial). <i>American Journal of Cardiology</i> , 2014 , 113, 1457-60 | 3 | 32 |
| 347 | Impact of extracardiac vascular disease on vein graft failure and outcomes after coronary artery bypass surgery. <i>Annals of Thoracic Surgery</i> , 2014 , 97, 824-30 | 2.7 | 10 |
| 346 | Design and rationale of the ANALYZE ST study: a prospective, nonrandomized, multicenter ST monitoring study to detect acute coronary syndrome events in implantable cardioverter-defibrillator patients. <i>American Heart Journal</i> , 2014 , 168, 424-429.e1 | 4.9 | 4 |
| 345 | Endoscopic harvesting device type and outcomes in patients undergoing coronary artery bypass surgery. <i>Annals of Surgery</i> , 2014 , 260, 402-8 | 7.8 | 14 |

| | | | |
|-----|--|------|-----|
| 344 | Angiographic validation of the American College of Cardiology Foundation-the Society of Thoracic Surgeons Collaboration on the Comparative Effectiveness of Revascularization Strategies study. <i>Circulation: Cardiovascular Interventions</i> , 2014 , 7, 11-8 | 6 | 10 |
| 343 | Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial. <i>Clinical Cardiology</i> , 2014 , 37, 160-6 | 3.3 | 3 |
| 342 | A reevaluation of the costs of heart failure and its implications for allocation of health resources in the United States. <i>Clinical Cardiology</i> , 2014 , 37, 312-21 | 3.3 | 89 |
| 341 | Relationship between ST-segment resolution and anterior infarct size after primary percutaneous coronary intervention: analysis from the INFUSE-AMI trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014 , 3, 78-83 | 4.3 | 19 |
| 340 | Advances in understanding percutaneous coronary intervention pharmacology: ischemia, bleeding, the ISAR research group, and a commitment to progress. <i>Coronary Artery Disease</i> , 2014 , 25, 453-5 | 1.4 | |
| 339 | Does Serum Bilirubin level on admission predict TIMI flow grade and in-hospital MACE in patients with STEMI undergoing primary PCI. <i>Angiology</i> , 2014 , 65, 198-204 | 2.1 | 44 |
| 338 | Vein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the PREVENT IV randomized clinical trial. <i>JAMA Surgery</i> , 2014 , 149, 798-805 | 5.4 | 52 |
| 337 | Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014 , 3, 37-45 | 4.3 | 47 |
| 336 | Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 619-629 | 15.1 | 73 |
| 335 | The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. <i>American Heart Journal</i> , 2014 , 167, 335-41 | 4.9 | 69 |
| 334 | Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2014 , 37, 310-6 | 5.1 | 9 |
| 333 | Impact of advanced age on myocardial perfusion, distal embolization, and mortality patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors. <i>Heart and Vessels</i> , 2014 , 29, 15-20 | 2.1 | 15 |
| 332 | Infarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: the Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial. <i>American Heart Journal</i> , 2013 , 166, 64-70 | 4.9 | 24 |
| 331 | Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. <i>Lancet, The</i> , 2013 , 382, 1714-22 | 4.0 | 405 |
| 330 | Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 36, 384-93 | 5.1 | 10 |
| 329 | Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 36, 233-9 | 5.1 | 9 |
| 328 | Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. <i>Lancet, The</i> , 2013 , 382, 1981-92 | 4.0 | 234 |
| 327 | Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. <i>American Heart Journal</i> , 2013 , 166, 723-8 | 4.9 | 20 |

| | | | |
|-----|---|-----|----|
| 326 | Impact of hypertension on distal embolization, myocardial perfusion, and mortality in patients with ST segment elevation myocardial infarction undergoing primary angioplasty. <i>American Journal of Cardiology</i> , 2013 , 112, 1083-6 | 3 | 12 |
| 325 | Relation between white blood cell count and final infarct size in patients with ST-segment elevation acute myocardial infarction undergoing primary percutaneous coronary intervention (from the INFUSE AMI trial). <i>American Journal of Cardiology</i> , 2013 , 112, 1860-6 | 3 | 14 |
| 324 | Balloon Angioplasty 2013 , 105-117 | | |
| 323 | Ostial Lesions 2013 , 255-267 | | |
| 322 | Retrograde Percutaneous Aortic Valvuloplasty 2013 , 475-486 | | |
| 321 | Infrainguinal and Infragenicular Interventions 2013 , 603-628 | | |
| 320 | Bifurcation Lesion 2013 , 313-345 | | |
| 319 | Inoue Balloon Mitral Valvuloplasty 2013 , 437-473 | | |
| 318 | Percutaneous Implantation of Aortic Valvular Prostheses 2013 , 487-500 | | |
| 317 | Relationship between myocardial reperfusion, infarct size, and mortality: the INFUSE-AMI (Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction) trial. <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, 718-24 | 5 | 34 |
| 316 | Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, 671-83 | 5 | 26 |
| 315 | Rationale and design of the EMBRACE STEMI study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2013 , 165, 509-514.e7 | 4.9 | 65 |
| 314 | Acute ST-Segment Elevation Myocardial Infarction 2013 , 269-292 | | |
| 313 | Guides 2013 , 51-86 | | |
| 312 | Slender Transradial Intervention 2013 , 171-183 | | |
| 311 | Percutaneous Intervention of Cardiac Congenital Anomalies 2013 , 629-656 | | |
| 310 | Angiographic Views 2013 , 27-49 | | |
| 309 | Transradial Approach 2013 , 141-169 | | |

308 High-Risk Patients **2013**, 399-417

307 Renal Artery Interventions **2013**, 537-551

306 Iliac Artery Stenosis **2013**, 579-602

1

305 Wires **2013**, 87-103

304 Left Main **2013**, 185-205

303 Interventions in Patients after Coronary Artery Bypass Graft Surgery **2013**, 293-311

302 Endovascular Repair of Abdominal Aortic Aneurysm **2013**, 517-535

301 Stenting **2013**, 119-140

300 Chronic Total Occlusion **2013**, 207-254

1

299 Removal of Embolized Material **2013**, 419-436

298 Subclavian Artery Interventions **2013**, 501-515

297 Carotid Artery Occlusive Disease **2013**, 553-578

296 Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. *Journal of the American College of Cardiology*, **2013**, 62, 242-251 15.1 29

295 Effect of Optison on pulmonary artery systolic pressure and pulmonary vascular resistance. *American Journal of Cardiology*, **2013**, 112, 1657-61 3 12

294 Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. *International Journal of Cardiology*, **2013**, 167, 1772-82 3.2 53

293 Triple Antiplatelet Therapy and Combinations with Oral Anticoagulants After Stent Implantation. *Interventional Cardiology Clinics*, **2013**, 2, 595-606 1.4

292 Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial. *International Journal of Cardiology*, **2013**, 167, 2580-7 3.2 11

291 Usefulness of monocyte chemoattractant protein-1 to predict no-reflow and three-year mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. *American Journal of Cardiology*, **2013**, 112, 187-93 3 14

| | | | |
|-----|---|------|-----|
| 290 | Prevalence, consequences, and implications for clinical trials of unrecognized myocardial infarction. <i>American Journal of Cardiology</i> , 2013 , 111, 914-8 | 3 | 48 |
| 289 | Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 469-477 | 15.1 | 141 |
| 288 | A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. <i>Heart</i> , 2013 , 99, 1282-7 | 5.1 | 27 |
| 287 | Association of time to reperfusion with left ventricular function and heart failure in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: a systematic review. <i>American Heart Journal</i> , 2013 , 165, 451-67 | 4.9 | 29 |
| 286 | Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 286-90 | 15.1 | 72 |
| 285 | Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 449-57 | 15.1 | 78 |
| 284 | Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51). <i>Journal of the American College of Cardiology</i> , 2013 , 61, 1853-9 | 15.1 | 80 |
| 283 | Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51). <i>American Journal of Cardiology</i> , 2013 , 112, 472-8 | 3 | 32 |
| 282 | Effect of platelet inhibition with cangrelor during PCI on ischemic events. <i>New England Journal of Medicine</i> , 2013 , 368, 1303-13 | 59.2 | 560 |
| 281 | Intralesional abciximab and thrombus aspiration in patients with large anterior myocardial infarction: one-year results from the INFUSE-AMI trial. <i>Circulation: Cardiovascular Interventions</i> , 2013 , 6, 527-34 | 6 | 48 |
| 280 | Response to letter regarding article, Sustained ventricular tachycardia and ventricular fibrillation complicating nonST-segment elevation acute coronary syndromes. <i>Circulation</i> , 2013 , 127, e634 | 16.7 | 0 |
| 279 | Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial. <i>Coronary Artery Disease</i> , 2013 , 24, 321-7 | 1.4 | 2 |
| 278 | Intracoronary bolus-only compared with intravenous bolus plus infusion of tirofiban application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2012 , 79, 59-67 | 2.7 | 20 |
| 277 | Patients with tombstoning pattern on the admission electrocardiography who have undergone primary percutaneous coronary intervention for anterior wall ST-elevation myocardial infarction: in-hospital and midterm clinical outcomes. <i>Annals of Noninvasive Electrocardiology</i> , 2012 , 17, 315-22 | 1.5 | 2 |
| 276 | Thrombolytics and myocardial infarction. <i>Cardiovascular Therapeutics</i> , 2012 , 30, e81-8 | 3.3 | 28 |
| 275 | Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. <i>American Heart Journal</i> , 2012 , 163, 182-90.e4 | 4.9 | 83 |
| 274 | Rationale and design of the Cangrelor versus standard therapy to achieve optimal Management of Platelet Inhibition PHOENIX trial. <i>American Heart Journal</i> , 2012 , 163, 768-776.e2 | 4.9 | 64 |
| 273 | Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. <i>American Journal of Cardiology</i> , 2012 , 110, 621-7 | 3 | 164 |

272 Newer Pharmaceutical Agents for STEMI Interventions. *Interventional Cardiology Clinics*, **2012**, 1, 429-440.4

271 Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. *JACC: Cardiovascular Interventions*, **2012**, 5, 327-35

270 Significance of false negative electrocardiograms in preparticipation screening of athletes for hypertrophic cardiomyopathy. *American Journal of Cardiology*, **2012**, 110, 1027-32

269 Atherosclerotic risk factors and their association with hospital mortality among patients with first myocardial infarction (from the National Registry of Myocardial Infarction). *American Journal of Cardiology*, **2012**, 110, 1256-61

268 Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes. *Expert Opinion on Drug Metabolism and Toxicology*, **2012**, 8, 889-900

267 Rivaroxaban in patients with a recent acute coronary syndrome. *New England Journal of Medicine*, **2012**, 366, 9-19

266 Intermediate-signal-intensity late gadolinium enhancement predicts ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy. *Circulation: Cardiovascular Imaging*, **2012**, 5, 78-85

265 Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. *American Journal of Cardiology*, **2012**, 109, 486-91

264 Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery. *Circulation*, **2012**, 125, 749-56

263 Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. *JAMA - Journal of the American Medical Association*, **2012**, 307, 1817-26

262 Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. *Circulation*, **2012**, 126, 41-9

261 Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy. *Circulation: Cardiovascular Imaging*, **2012**, 5, 441-7

260 A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y₁₂ inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. *Circulation: Cardiovascular Interventions*, **2012**, 5, 336-46

259 Optimal selection of STEMI treatment strategies in the current era: benefit of transferring STEMI patients for PCI compared with administration of onsite fibrinolytic therapy. *Current Opinion in Cardiology*, **2012**, 27, 651-4

258 Relation of red cell distribution width with the presence, severity, and complexity of coronary artery disease. *Coronary Artery Disease*, **2012**, 23, 51-6

257 Cost-Effective Medicines for Stroke Prophylaxis in Patients with Atrial Fibrillation. *Journal of Atrial Fibrillation*, **2012**, 5, 470

256 Rationale and design of the INFUSE-AMI study: A 2 X 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. *American Heart Journal*, **2011**, 161, 478-486.e7

255 Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. *American Heart Journal*, **2011**, 161, 815-821.e6

| | | | |
|-----|---|------|------|
| 254 | Association of initial thrombolysis in myocardial infarction flow grade with mortality among patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a National Registry of Myocardial Infarction-5 (NRM-5) analysis. <i>American Heart Journal</i> , 2011 , 162, 178-83 | 4.9 | 9 |
| 253 | Hemoglobin A1c as a prognostic marker in patients undergoing primary angioplasty for acute myocardial infarction. <i>Coronary Artery Disease</i> , 2011 , 22, 131-7 | 1.4 | 31 |
| 252 | Red cell distribution width as a novel prognostic marker in patients undergoing primary angioplasty for acute myocardial infarction. <i>Coronary Artery Disease</i> , 2011 , 22, 138-44 | 1.4 | 113 |
| 251 | Relation of circulating osteoprotegerin levels on admission to microvascular obstruction after primary percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2011 , 107, 857-62 | 3 | 8 |
| 250 | Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2011 , 31, 493-500 | 5.1 | 7 |
| 249 | Coronary flow reserve varies depending upon the location within the artery it is assessed and the TIMI myocardial perfusion grade: a PROTECT TIMI-30 analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2011 , 32, 448-52 | 5.1 | 1 |
| 248 | Percutaneous coronary interventions in facilities without cardiac surgery on site. <i>Current Cardiology Reports</i> , 2011 , 13, 432-8 | 4.2 | 2 |
| 247 | Intracoronary delivery of eptifibatide with the ClearWay [®] RX infusion catheter. <i>Catheterization and Cardiovascular Interventions</i> , 2011 , 77, 222-7 | 2.7 | 2 |
| 246 | RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. <i>European Heart Journal</i> , 2011 , 32, 2541-54 | 9.5 | 142 |
| 245 | Early vs. delayed invasive strategy in patients with acute coronary syndromes without ST-segment elevation: a meta-analysis of randomized studies. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011 , 104, 193-200 | 2.7 | 33 |
| 244 | Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. <i>Radiology</i> , 2011 , 258, 128-33 | 20.5 | 107 |
| 243 | Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 2120-7 | 27.4 | 128 |
| 242 | Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. <i>Circulation</i> , 2011 , 123, 2736-47 | 16.7 | 2467 |
| 241 | Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. <i>Circulation</i> , 2011 , 124, 40-7 | 16.7 | 251 |
| 240 | Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial. <i>Circulation</i> , 2011 , 124, 280-8 | 16.7 | 86 |
| 239 | Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. <i>Circulation</i> , 2011 , 124, 2512-21 | 16.7 | 123 |
| 238 | Incremental benefit of 80-lead electrocardiogram body surface mapping over the 12-lead electrocardiogram in the detection of acute coronary syndromes in patients without ST-elevation myocardial infarction: Results from the Optimal Cardiovascular Diagnostic Evaluation Enabling Faster Treatment of Myocardial Infarction (OCCULT MI) trial. <i>Academic Emergency Medicine</i> , 2010 , Moving toward improved care for the patient with ST-elevation myocardial infarction: a mandate for systems of care. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010 , 3, 441-3 | 3.4 | 11 |
| 237 | | 5.8 | 12 |

| | | | |
|-----|---|------|-----|
| 236 | Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. <i>Circulation</i> , 2010 , 121, 784-91 | 16.7 | 83 |
| 235 | Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. <i>European Heart Journal</i> , 2010 , 31, 2103-10 | 9.5 | 33 |
| 234 | Initial clinical results using intracardiac electrogram monitoring to detect and alert patients during coronary plaque rupture and ischemia. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1089-98 | 15.1 | 38 |
| 233 | Diagnostic accuracy of 64-slice multidetector CT for detection of in-stent restenosis in an unselected, consecutive patient population. <i>European Journal of Radiology</i> , 2010 , 76, 188-94 | 4.7 | 21 |
| 232 | Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVALuate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). <i>American Heart Journal</i> , 2010 , 160, 65-72 | 4.9 | 65 |
| 231 | Intensive statin therapy: a goal worth targeting. <i>Interventional Cardiology</i> , 2010 , 2, 103-105 | 3 | |
| 230 | Impact of distal embolization on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation. <i>Journal of Thrombosis and Thrombolysis</i> , 2010 , 30, 23-8 | 5.1 | 11 |
| 229 | Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation. <i>Journal of Thrombosis and Thrombolysis</i> , 2010 , 30, 342-6 | 5.1 | 31 |
| 228 | Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes. <i>Journal of Thrombosis and Thrombolysis</i> , 2010 , 30, 10-3 | 5.1 | 3 |
| 227 | Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. <i>American Journal of Cardiology</i> , 2010 , 106, 261-7 | 3 | 111 |
| 226 | Relation between infarct size in ST-segment elevation myocardial infarction treated successfully by percutaneous coronary intervention and left ventricular ejection fraction three months after the infarct. <i>American Journal of Cardiology</i> , 2010 , 106, 635-40 | 3 | 23 |
| 225 | Adjunctive transcutaneous ultrasound with thrombolysis: results of the PLUS (Perfusion by ThromboLytic and UltraSound) trial. <i>JACC: Cardiovascular Interventions</i> , 2010 , 3, 352-9 | 5 | 15 |
| 224 | Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. <i>JACC: Cardiovascular Interventions</i> , 2010 , 3, 806-11 | 5 | 60 |
| 223 | Fractional flow reserve: a new set of lenses for the occulostenotic reflex?. <i>JACC: Cardiovascular Interventions</i> , 2010 , 3, 1282-3 | 5 | 2 |
| 222 | Intravenous platelet blockade with cangrelor during PCI. <i>New England Journal of Medicine</i> , 2009 , 361, 2330-41 | 59.2 | 480 |
| 221 | Platelet inhibition with cangrelor in patients undergoing PCI. <i>New England Journal of Medicine</i> , 2009 , 361, 2318-29 | 59.2 | 454 |
| 220 | Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. <i>European Heart Journal</i> , 2009 , 30, 1195-202 | 9.5 | 120 |
| 219 | Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. <i>New England Journal of Medicine</i> , 2009 , 361, 235-44 | 59.2 | 264 |

| | | | |
|-----|--|-----|-----|
| 218 | Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial. <i>Circulation: Cardiovascular Interventions</i> , 2009 , 2, 43-51 | 6 | 16 |
| 217 | Outcomes among patients with ST-segment-elevation myocardial infarction presenting to interventional hospitals with and without on-site cardiac surgery. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009 , 2, 574-82 | 5.8 | 28 |
| 216 | Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study). <i>American Journal of Cardiology</i> , 2009 , 103, 1056-60 | 3 | 28 |
| 215 | Predicting irreversible left ventricular dysfunction after acute myocardial infarction. <i>American Journal of Cardiology</i> , 2009 , 103, 1206-9 | 3 | 7 |
| 214 | Timing and duration of myocardial ischemia on Holter monitoring following percutaneous coronary intervention and their association with clinical outcomes (a PROTECT-TIMI 30 Substudy Analysis). <i>American Journal of Cardiology</i> , 2009 , 104, 36-40 | 3 | 4 |
| 213 | Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2009 , 104, 475-9 | 3 | 17 |
| 212 | Outcomes among patients with non-ST-segment elevation myocardial infarction presenting to interventional hospitals with and without on-site cardiac surgery. <i>JACC: Cardiovascular Interventions</i> , 2009 , 2, 944-52 | 5 | 14 |
| 211 | Association of TIMI myocardial perfusion grade and ST-segment resolution with cardiovascular magnetic resonance measures of microvascular obstruction and infarct size following ST-segment elevation myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2009 , 27, 123-9 | 5.1 | 26 |
| 210 | Association of angiographic perfusion score following percutaneous coronary intervention for ST-elevation myocardial infarction with left ventricular remodeling at 6 weeks in GRACIA-2. <i>Journal of Thrombosis and Thrombolysis</i> , 2009 , 27, 253-8 | 5.1 | 4 |
| 209 | Use of the TIMI frame count in the assessment of coronary artery blood flow and microvascular function over the past 15 years. <i>Journal of Thrombosis and Thrombolysis</i> , 2009 , 27, 316-28 | 5.1 | 33 |
| 208 | Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an EXTRACT-TIMI 25 analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2009 , 27, 11-7 | 5.1 | 19 |
| 207 | Transfusion associated microchimerism: a heretofore little-recognized complication following transfusion. <i>Journal of Thrombosis and Thrombolysis</i> , 2009 , 27, 57-67 | 5.1 | 7 |
| 206 | Benefits of pharmacological facilitation with glycoprotein IIb-IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperation. <i>Journal of Thrombosis and Thrombolysis</i> , 2009 , 28, 288-98 | 5.1 | 11 |
| 205 | Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography. <i>American Heart Journal</i> , 2009 , 157, 716-23 | 4.9 | 102 |
| 204 | Association of Thrombolysis in Myocardial Infarction Myocardial Perfusion Grade with cardiovascular magnetic resonance measures of infarct architecture after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2009 , 158, 84-91 | 4.9 | 15 |
| 203 | Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRIal to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibition with prasugrel (PRADO). <i>Thrombolysis in Myocardial Infarction (TIMI) 28</i> . <i>Journal of Thrombosis and Thrombolysis</i> , 2009 , 28, 100-10 | 4.9 | 25 |
| 202 | Association between advanced Killip class at presentation and impaired myocardial perfusion among patients with ST-segment elevation myocardial infarction treated with primary angioplasty and adjunctive glycoprotein IIb-IIIa inhibitors. <i>American Heart Journal</i> , 2009 , 158, 416-21 | 4.9 | 15 |
| 201 | Hospitals with and without percutaneous coronary intervention capability: considerations for treating acute coronary syndromes. <i>American Journal of Emergency Medicine</i> , 2009 , 27, 595-606 | 2.9 | 1 |

| | | | |
|-----|--|------|-----|
| 200 | Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 220-8 | 15.1 | 304 |
| 199 | Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. <i>Circulation</i> , 2009 , 119, 2000-5 | 15.1 | 82 |
| 198 | Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb/IIIa inhibitors. <i>Atherosclerosis</i> , 2009 , 207, 181-5 | 3.1 | 77 |
| 197 | Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. <i>Lancet, The</i> , 2009 , 373, 723-31 | 40 | 834 |
| 196 | Underestimation of the effect of bleeding in clinical trials. Authors' reply. <i>Lancet, The</i> , 2009 , 374, 1145-1146 | 146 | 1 |
| 195 | Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study). <i>American Journal of Cardiology</i> , 2008 , 101, 303-7 | 3 | 55 |
| 194 | Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. <i>American Journal of Cardiology</i> , 2008 , 101, 668-73 | 3 | 107 |
| 193 | Relation of hyperemic epicardial flow to outcomes among patients with ST-segment elevation myocardial infarction receiving fibrinolytic therapy. <i>American Journal of Cardiology</i> , 2008 , 101, 1232-8 | 3 | 6 |
| 192 | Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PProject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV). <i>American Journal of Cardiology</i> , 2008 , 102, 546-51 | 3 | 54 |
| 191 | Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008 , 136, 1149-55 | 1.5 | 16 |
| 190 | Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 546-51 | 15.1 | 25 |
| 189 | Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 1369-74 | 15.1 | 509 |
| 188 | The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes. <i>International Journal of Cardiology</i> , 2008 , 131, 105-12 | 3.2 | 2 |
| 187 | Coronary artery bypass graft failure after on-pump and off-pump coronary artery bypass: findings from PREVENT IV. <i>Annals of Thoracic Surgery</i> , 2008 , 85, 494-9; discussion 499-500 | 2.7 | 87 |
| 186 | Impact of saphenous vein graft radiographic markers on clinical events and angiographic parameters. <i>Annals of Thoracic Surgery</i> , 2008 , 85, 520-4 | 2.7 | 5 |
| 185 | Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study. <i>American Heart Journal</i> , 2008 , 155, 133-9 | 4.9 | 10 |
| 184 | Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: results of a multicenter case-control study with 145 thrombosis events. <i>American Heart Journal</i> , 2008 , 155, 654-60 | 4.9 | 24 |
| 183 | Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. <i>American Heart Journal</i> , 2008 , 156, 1045-55 | 4.9 | 180 |

| | | | |
|-----|---|------|------|
| 182 | Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. <i>American Heart Journal</i> , 2008 , 156, 1035-44 | 4.9 | 199 |
| 181 | Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. <i>American Heart Journal</i> , 2008 , 156, 1026-34 | 4.9 | 284 |
| 180 | Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. <i>European Heart Journal</i> , 2008 , 29, 984-91 | 9.5 | 40 |
| 179 | Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. <i>Circulation: Heart Failure</i> , 2008 , 1, 184-91 | 7.6 | 224 |
| 178 | Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. <i>Circulation</i> , 2008 , 117, 886-96 | 16.7 | 176 |
| 177 | Vascular endothelial growth factors in pulmonary edema: an update. <i>Journal of Thrombosis and Thrombolysis</i> , 2008 , 25, 259-64 | 5.1 | 27 |
| 176 | Angiographic perfusion score in patients treated with PCI at late angiography following fibrinolytic administration for ST-segment elevation myocardial infarction is associated with morbidity and mortality at 30 days. <i>Journal of Thrombosis and Thrombolysis</i> , 2008 , 26, 106-12 | 5.1 | 2 |
| 175 | Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction. <i>Journal of Thrombosis and Thrombolysis</i> , 2008 , 26, 234-42 | 5.1 | 20 |
| 174 | Introduction. Key issues surrounding the treatment of acute coronary syndromes (ACS). <i>Journal of Interventional Cardiology</i> , 2008 , 21 Suppl 1, S1-2 | 1.8 | |
| 173 | Antiplatelet therapy: anti-ischemic benefits versus bleeding risk. <i>Journal of Interventional Cardiology</i> , 2008 , 21 Suppl 1, S3-9 | 1.8 | 4 |
| 172 | Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 2238-46 | 15.1 | 100 |
| 171 | Delayed-enhancement cardiovascular magnetic resonance coronary artery wall imaging: comparison with multislice computed tomography and quantitative coronary angiography. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 441-7 | 15.1 | 89 |
| 170 | Prasugrel versus clopidogrel in patients with acute coronary syndromes. <i>New England Journal of Medicine</i> , 2007 , 357, 2001-15 | 59.2 | 4824 |
| 169 | Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). <i>American Journal of Cardiology</i> , 2007 , 99, 1389-93 | 3 | 21 |
| 168 | Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (A REPLACE-2 analysis). <i>American Journal of Cardiology</i> , 2007 , 99, 1687-90 | 3 | 23 |
| 167 | Impact of iodinated contrast injections on percent diameter coronary arterial stenosis and implications for trials of intracoronary pharmacotherapies in patients with ST-elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2007 , 100, 13-7 | 3 | 2 |
| 166 | Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes. <i>American Journal of Cardiology</i> , 2007 , 100, 1734-8 | 3 | 19 |
| 165 | Reperfusion strategies for ST-elevation myocardial infarction. <i>Current Cardiology Reports</i> , 2007 , 9, 281-84.2 | | 6 |

| | | | |
|-----|---|------|-----|
| 164 | Diagnostic and prognostic value of ambulatory ECG (Holter) monitoring in patients with coronary heart disease: a review. <i>Journal of Thrombosis and Thrombolysis</i> , 2007 , 23, 135-45 | 5.1 | 24 |
| 163 | Advances in antithrombin and antiplatelet therapy for percutaneous coronary intervention. <i>Current Cardiovascular Risk Reports</i> , 2007 , 1, 284-289 | 0.9 | |
| 162 | Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. <i>European Heart Journal</i> , 2007 , 28, 949-60 | 9.5 | 106 |
| 161 | Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. <i>Chest</i> , 2007 , 131, 964-71 | 5.3 | 107 |
| 160 | Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18. <i>European Heart Journal</i> , 2007 , 28, 806-13 | 9.5 | 38 |
| 159 | Global outcomes of ST-elevation myocardial infarction: comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (EXTRACT-TIMI 25) registry and trial. <i>American Heart Journal</i> , 2007 , 154, 54-61 | 4.9 | 14 |
| 158 | Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. <i>American Heart Journal</i> , 2007 , 154, 702-9 | 4.9 | 56 |
| 157 | Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. <i>Annals of Thoracic Surgery</i> , 2007 , 83, 993-1001 | 2.7 | 76 |
| 156 | Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. <i>European Heart Journal</i> , 2007 , 28, 2077-86 | 9.5 | 143 |
| 155 | Enoxaparin in acute coronary syndromes. <i>Expert Review of Cardiovascular Therapy</i> , 2007 , 5, 387-99 | 2.5 | 8 |
| 154 | Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. <i>American Journal of Cardiology</i> , 2006 , 97, 1473-7 | 3 | 27 |
| 153 | Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial. <i>American Journal of Cardiology</i> , 2006 , 97, 1573-7 | 3 | 38 |
| 152 | Potential for drug-drug interactions in patients taking analgesics for mild-to-moderate pain and low-dose aspirin for cardioprotection. <i>American Journal of Cardiology</i> , 2006 , 97, 23-9 | 3 | 23 |
| 151 | Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28). <i>American Journal of Cardiology</i> , 2006 , 98, 761-3 | 3 | 17 |
| 150 | Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. <i>European Heart Journal</i> , 2006 , 27, 2310-6 | 9.5 | 52 |
| 149 | Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy. <i>European Heart Journal</i> , 2006 , 27, 2040-5 | 9.5 | 14 |
| 148 | The association of impaired myocardial perfusion and monocyteosis with late recovery of left ventricular function following primary percutaneous coronary intervention. <i>European Heart Journal</i> , 2006 , 27, 2487-8 | 9.5 | 3 |
| 147 | Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. <i>Circulation</i> , 2006 , 114, 2019-25 | 16.7 | 386 |

| | | | |
|-----|--|------|-----|
| 146 | Characterization of microvascular dysfunction after acute myocardial infarction by cardiovascular magnetic resonance first-pass perfusion and late gadolinium enhancement imaging. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2006 , 8, 831-7 | 6.9 | 52 |
| 145 | Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 2374-9 | 15.1 | 98 |
| 144 | A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 2364-73 | 15.1 | 106 |
| 143 | The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 37-42 | 15.1 | 53 |
| 142 | Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. <i>American Heart Journal</i> , 2006 , 152, 668-75 | 4.9 | 83 |
| 141 | Distal embolization of thrombus in acute myocardial infarction. <i>American Journal of Medicine</i> , 2006 , 119, e1-2 | 2.4 | 170 |
| 140 | Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarction. <i>American Heart Journal</i> , 2006 , 151, 25-31 | 4.9 | 16 |
| 139 | Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative. <i>American Heart Journal</i> , 2006 , 152, 641-7 | 4.9 | 133 |
| 138 | Door-to-balloon delays with percutaneous coronary intervention in ST-elevation myocardial infarction. <i>American Heart Journal</i> , 2006 , 151, S24-9 | 4.9 | 9 |
| 137 | Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet Inhibition with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). <i>American Heart Journal</i> , 2006 , 152, 627-35 | 4.9 | 251 |
| 136 | Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTION against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 2374-9 | 4.9 | 27 |
| 135 | Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome. <i>Journal of Clinical Hypertension</i> , 2006 , 8, 315-22 | 2.3 | 19 |
| 134 | Early invasive strategy improves outcomes in patients with acute coronary syndrome with previous coronary artery bypass graft surgery: a report from TACTICS-TIMI 18. <i>Critical Pathways in Cardiology</i> , 2006 , 5, 167-72 | 1.3 | 18 |
| 133 | Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina. <i>Journal of Thrombosis and Thrombolysis</i> , 2006 , 22, 47-50 | 5.1 | 23 |
| 132 | Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: results of the TIMI 31 trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2006 , 22, 13-21 | 5.1 | 6 |
| 131 | Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy. <i>European Heart Journal</i> , 2005 , 26, 440-6 | 9.5 | 45 |
| 130 | Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. <i>American Heart Journal</i> , 2005 , 149, 846-50 | 4.9 | 43 |
| 129 | Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. <i>American Heart Journal</i> , 2005 , 149, 227-33 | 4.9 | 43 |

| | | | |
|-----|--|------|------|
| 128 | Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial. <i>American Heart Journal</i> , 2005 , 150, 79-88 | 4.9 | 8 |
| 127 | The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome—study design and rationale. <i>American Heart Journal</i> , 2005 , 149, 994-1002 | 4.9 | 75 |
| 126 | The PROject of Ex-vivo Vein graft ENGINEERING via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics. <i>American Heart Journal</i> , 2005 , 150, 643-9 | 4.9 | 45 |
| 125 | Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 321-3 | 15.1 | 26 |
| 124 | Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 357-62 | 15.1 | 11 |
| 123 | Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 1781-6 | 15.1 | 88 |
| 122 | U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 178-80 | 15.1 | 125 |
| 121 | Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 1417-24 | 15.1 | 99 |
| 120 | Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. <i>New England Journal of Medicine</i> , 2005 , 352, 1179-89 | 59.2 | 1508 |
| 119 | Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. <i>Annals of Internal Medicine</i> , 2005 , 142, 786-91 | 8 | 313 |
| 118 | Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2005 , 95, 228-33 | 3 | 3 |
| 117 | Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2005 , 95, 224-7 | 3 | 2 |
| 116 | Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy. <i>American Journal of Cardiology</i> , 2005 , 95, 337-42 | 3 | 4 |
| 115 | Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2005 , 95, 383-6 | 3 | 20 |
| 114 | C-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 trial). <i>American Journal of Cardiology</i> , 2005 , 96, 635-8 | 3 | 6 |
| 113 | Outcome in patients transferred for percutaneous coronary intervention (a national registry of myocardial infarction 2/3/4 analysis). <i>American Journal of Cardiology</i> , 2005 , 96, 1227-32 | 3 | 43 |
| 112 | Administration of intracoronary eptifibatide during ST-elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2005 , 96, 1494-7 | 3 | 18 |
| 111 | Current Assessments of the Adequacy of Myocardial Perfusion During Acute MI. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2005 , 7, 25-34 | 2.1 | |

| | | | |
|-----|---|------|-----|
| 110 | Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. <i>Circulation</i> , 2005 , 111, 2042-9 | 16.7 | 487 |
| 109 | Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment. <i>Circulation</i> , 2005 , 111, 1217-24 | 16.7 | 47 |
| 108 | Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 294, 3108-16 | 27.4 | 498 |
| 107 | Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 294, 1224-32 | 27.4 | 521 |
| 106 | Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. <i>European Heart Journal</i> , 2004 , 25, 1998-2005 | 9.5 | 109 |
| 105 | Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. <i>Circulation</i> , 2004 , 110, 478-84 | 16.7 | 43 |
| 104 | Coronary and myocardial angiography: angiographic assessment of both epicardial and myocardial perfusion. <i>Circulation</i> , 2004 , 109, 3096-105 | 16.7 | 128 |
| 103 | Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. <i>Circulation</i> , 2004 , 109, 588-9 | 16.7 | 144 |
| 102 | Time is muscle in primary PCI: the strength of the evidence grows. <i>European Heart Journal</i> , 2004 , 25, 1001-2 | 9.5 | 23 |
| 101 | Severity of heart failure, treatments, and outcomes after fibrinolysis in patients with ST-elevation myocardial infarction. <i>European Heart Journal</i> , 2004 , 25, 1702-10 | 9.5 | 24 |
| 100 | Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 292, 2096-104 | 27.4 | 412 |
| 99 | The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies. <i>European Heart Journal</i> , 2004 , 25, 1139-45 | 9.5 | 15 |
| 98 | Timing of angiography and revascularization in acute coronary syndromes: an analysis of the TACTICS-TIMI-18 trial. <i>Journal of Interventional Cardiology</i> , 2004 , 17, 81-6 | 1.8 | 22 |
| 97 | Association of peripheral neutrophilia with adverse angiographic outcomes in ST-elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2004 , 93, 532-6 | 3 | 80 |
| 96 | Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. <i>American Journal of Cardiology</i> , 2004 , 93, 1362-7, A5-6 | 3 | 36 |
| 95 | Association of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2004 , 94, 108-11 | 3 | 4 |
| 94 | Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy). <i>American Journal of Cardiology</i> , 2004 , 94, 492-4 | 3 | 14 |
| 93 | Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2004 , 94, 1113-7 | 3 | 6 |

| | | | |
|----|---|------|-----|
| 92 | Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2004 , 94, 1406-10 | 3 | 27 |
| 91 | Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2004 , 94, 1537-9 | 3 | 7 |
| 90 | Association of epicardial and tissue-level reperfusion with left ventricular end-diastolic pressures in ST-elevation myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2004 , 17, 177-84 | 5.1 | 23 |
| 89 | Door-to-Balloon Delays with PCI in Acute Myocardial Infarction. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2004 , 6, 69-77 | 2.1 | 4 |
| 88 | Myonecrosis following stent placement: association between impaired TIMI myocardial perfusion grade and MRI visualization of microinfarction. <i>Catheterization and Cardiovascular Interventions</i> , 2004 , 61, 472-6 | 2.7 | 41 |
| 87 | Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 549-56 | 15.1 | 24 |
| 86 | Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 1170-6 | 15.1 | 6 |
| 85 | Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 564-8 | 15.1 | 99 |
| 84 | A risk score to estimate the likelihood of coronary artery bypass surgery during the index hospitalization among patients with unstable angina and non-ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 799-803 | 15.1 | 39 |
| 83 | B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 335-9 | 15.1 | 171 |
| 82 | Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 980-7 | 15.1 | 38 |
| 81 | Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction. <i>American Heart Journal</i> , 2004 , 147, 847-52 | 4.9 | 22 |
| 80 | Angiographic perfusion score: an angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction. <i>American Heart Journal</i> , 2004 , 148, 336-40 | 4.9 | 61 |
| 79 | NRMI and current treatment patterns for ST-elevation myocardial infarction. <i>American Heart Journal</i> , 2004 , 148, S29-33 | 4.9 | 56 |
| 78 | Greater benefit of early invasive strategy for unstable angina and non-ST elevation myocardial infarction in United States compared with non-United States patients: a TACTICS-TIMI 18 substudy. <i>Critical Pathways in Cardiology</i> , 2004 , 3, 95-100 | 1.3 | |
| 77 | Heart failure: an epidemic of the 21st century. <i>Critical Pathways in Cardiology</i> , 2004 , 3, 194-204 | 1.3 | 9 |
| 76 | Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. <i>Circulation</i> , 2003 , 107, 690-5 | 16.7 | 368 |
| 75 | Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture. <i>Journal of Thrombosis and Thrombolysis</i> , 2003 , 15, 189-96 | 5.1 | 39 |

| | | | |
|----|---|------|-----|
| 74 | The prognostic value of serum creatinine on admission in fibrinolytic-eligible patients with acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2003 , 16, 167-74 | 5.1 | 18 |
| 73 | Impairment of myocardial perfusion in both culprit and nonculprit arteries in acute myocardial infarction: a LIMIT AMI substudy. <i>American Journal of Cardiology</i> , 2003 , 91, 325-8 | 3 | 13 |
| 72 | Association of an activated clotting time American Journal of Cardiology, 2003 , 91, 976-8, A4 | 3 | 13 |
| 71 | Meta-analysis of corticosteroid treatment in acute myocardial infarction. <i>American Journal of Cardiology</i> , 2003 , 91, 1055-9 | 3 | 132 |
| 70 | Association between short-term simvastatin therapy before coronary artery bypass grafting and postoperative myocardial blood flow as assessed by positron emission tomography. <i>American Journal of Cardiology</i> , 2003 , 91, 1107-9 | 3 | 17 |
| 69 | Time for contrast material to traverse the epicardial artery and the myocardium in ST-segment elevation acute myocardial infarction versus unstable angina pectoris/non-ST-elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2003 , 91, 1163-7 | 3 | 8 |
| 68 | Association of the Fibonacci Cascade with the distribution of coronary artery lesions responsible for ST-segment elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2003 , 92, 595-7 | 3 | 18 |
| 67 | Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction. <i>American Journal of Cardiology</i> , 2003 , 92, 913-8 | 3 | 56 |
| 66 | Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. <i>Journal of the American College of Cardiology</i> , 2003 , 42, 1535-43 | 15.1 | 215 |
| 65 | Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. <i>Journal of the American College of Cardiology</i> , 2003 , 41, 1251-60 | 15.1 | 80 |
| 64 | Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. <i>Journal of the American College of Cardiology</i> , 2003 , 41, 1264-72 | 15.1 | 338 |
| 63 | Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. <i>Journal of the American College of Cardiology</i> , 2003 , 42, 7-16 | 15.1 | 130 |
| 62 | Angiographic and clinical characteristics associated with the development of Q-wave and non-Q-wave myocardial infarction in the thrombolysis in myocardial infarction (TIMI) 14 trial. <i>American Heart Journal</i> , 2003 , 146, 42-7 | 4.9 | 4 |
| 61 | Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry. <i>American Heart Journal</i> , 2003 , 145, 109-17 | 4.9 | 51 |
| 60 | The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. <i>Circulation</i> , 2003 , 107, 1359-65 | 16.7 | 869 |
| 59 | Safety and efficacy of tenecteplase in acute myocardial infarction. <i>Expert Opinion on Pharmacotherapy</i> , 2003 , 4, 791-8 | 4 | 13 |
| 58 | Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. <i>Circulation</i> , 2003 , 108, 951-7 | 16.7 | 98 |
| 57 | Has my patient achieved adequate myocardial reperfusion?. <i>Circulation</i> , 2003 , 108, 504-7 | 16.7 | 29 |

| | | | |
|----|--|------|-----|
| 56 | Soluble CD40L: risk prediction after acute coronary syndromes. <i>Circulation</i> , 2003 , 108, 1049-52 | 16.7 | 330 |
| 55 | Predictors of door-to-balloon delay in primary angioplasty. <i>American Journal of Cardiology</i> , 2002 , 89, 1156-61 | 3 | 121 |
| 54 | Comparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT I). <i>American Journal of Cardiology</i> , 2002 , 90, 51-4 | 3 | 9 |
| 53 | Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry. <i>American Journal of Cardiology</i> , 2002 , 90, 303-5 | 3 | 63 |
| 52 | Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes. <i>American Journal of Cardiology</i> , 2002 , 90, 631-3 | 3 | 43 |
| 51 | Impact of gender on angiographic and clinical outcomes after fibrinolytic therapy in acute myocardial infarction. <i>American Journal of Cardiology</i> , 2002 , 90, 766-70 | 3 | 14 |
| 50 | Predictors of mortality, coronary angiography, and revascularization in unstable angina pectoris and acute non-ST elevation myocardial infarction (the TIMI III Registry). <i>American Journal of Cardiology</i> , 2002 , 90, 1154-6 | 3 | 9 |
| 49 | Intra-aortic balloon pump placement following aorto-iliac angioplasty and stent placement. <i>Catheterization and Cardiovascular Interventions</i> , 2002 , 55, 163-8 | 2.7 | 10 |
| 48 | Initial clinical experience with distal protection using the FilterWire in patients undergoing coronary artery and saphenous vein graft percutaneous intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2002 , 57, 125-34 | 2.7 | 35 |
| 47 | Precordial ST-segment depression in inferior myocardial infarction is associated with slow flow in the non-culprit left anterior descending artery. <i>Journal of Thrombosis and Thrombolysis</i> , 2002 , 13, 9-12 | 5.1 | 5 |
| 46 | The relationship of intracoronary stent placement following thrombolytic therapy to tissue level perfusion. <i>Journal of Thrombosis and Thrombolysis</i> , 2002 , 13, 63-8 | 5.1 | 1 |
| 45 | The smoker's paradox: insights from the angiographic substudies of the TIMI trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2002 , 13, 133-9 | 5.1 | 43 |
| 44 | Methodologic and clinical validation of the TIMI myocardial perfusion grade in acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2002 , 14, 233-7 | 5.1 | 21 |
| 43 | Quantitative comparison of coronary artery flow and myocardial perfusion in patients with acute myocardial infarction in the presence and absence of recent cocaine use. <i>Journal of Thrombosis and Thrombolysis</i> , 2002 , 14, 239-45 | 5.1 | 14 |
| 42 | TIMI myocardial perfusion grade and ST segment resolution: association with infarct size as assessed by single photon emission computed tomography imaging. <i>Circulation</i> , 2002 , 105, 282-5 | 16.7 | 130 |
| 41 | Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. <i>Circulation</i> , 2002 , 105, 1760-3 | 16.7 | 562 |
| 40 | Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. <i>Circulation</i> , 2002 , 105, 1909-13 | 16.7 | 305 |
| 39 | Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. <i>Circulation</i> , 2002 , 105, 1642-9 | 16.7 | 190 |

| | | | |
|----|---|------|------|
| 38 | Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. <i>Circulation</i> , 2002 , 106, 202-7 | 16.7 | 104 |
| 37 | The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 238-44 | 15.1 | 44 |
| 36 | Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18 Trial) substudy. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 1761-8 | 15.1 | 204 |
| 35 | Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy. <i>American Heart Journal</i> , 2002 , 143, 106-10 | 4.9 | 40 |
| 34 | Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. <i>American Heart Journal</i> , 2002 , 144, 130-5 | 4.9 | 29 |
| 33 | Which patients with unstable angina or non-Q-wave myocardial infarction should have immediate cardiac catheterization? A clinical decision rule for predicting who will fail medical therapy. <i>Journal of Clinical Epidemiology</i> , 2002 , 55, 121-8 | 5.7 | 9 |
| 32 | Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration. <i>American Heart Journal</i> , 2002 , 144, 790-5 | 4.9 | 15 |
| 31 | Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. <i>Journal of Invasive Cardiology</i> , 2002 , 14, 299-302 | 0.7 | 64 |
| 30 | Combination Reperfusion Therapy with Eptifibatide and Tenecteplase for Acute Myocardial Infarction. <i>Cardiology</i> , 2001 , 1, 5-13 | | 11 |
| 29 | Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2001 , 53, 6-11 | 2.7 | 7 |
| 28 | Issues in the assessment of the safety and efficacy of tenecteplase (TNK-tPA). <i>Clinical Cardiology</i> , 2001 , 24, 577-84 | 3.3 | 13 |
| 27 | Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. <i>Circulation</i> , 2001 , 104, 2778-83 | 16.7 | 166 |
| 26 | Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. <i>Circulation</i> , 2001 , 103, 2550-4 | 16.7 | 366 |
| 25 | Use of reperfusion therapies in elderly patients with acute myocardial infarction. <i>Drugs and Aging</i> , 2001 , 18, 587-96 | 4.7 | 4 |
| 24 | Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. <i>New England Journal of Medicine</i> , 2001 , 344, 1879-87 | 59.2 | 1549 |
| 23 | Outcome of patients with acute myocardial infarction who are ineligible for primary angioplasty trials. <i>Catheterization and Cardiovascular Interventions</i> , 2000 , 49, 237-43 | 2.7 | 12 |
| 22 | Key references on a wide variety of topics pertaining to coronary artery blood flow and patency. <i>Journal of Thrombosis and Thrombolysis</i> , 2000 , 9, 85-93 | 5.1 | |
| 21 | Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. <i>Circulation</i> , 2000 , 102, 2329-34 | 16.7 | 294 |

| | | | |
|----|---|------|------|
| 20 | Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. <i>Circulation</i> , 2000 , 101, 239-43 | 16.7 | 218 |
| 19 | Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. <i>Circulation</i> , 2000 , 101, 125-30 | 16.7 | 707 |
| 18 | High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. <i>Circulation</i> , 2000 , 101, 2690-5 | 16.7 | 64 |
| 17 | Primary angioplasty compared with thrombolysis: new issues in the era of glycoprotein IIb/IIIa inhibition and intracoronary stenting. <i>Annals of Internal Medicine</i> , 1999 , 130, 841-7 | 8 | 24 |
| 16 | Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. <i>Circulation</i> , 1999 , 99, 2720-32 | 16.7 | 559 |
| 15 | Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. <i>Circulation</i> , 1999 , 99, 1945-50 | 16.7 | 318 |
| 14 | Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology. <i>Journal of Thrombosis and Thrombolysis</i> , 1999 , 7, 287-302 | 5.1 | 1 |
| 13 | The Open Artery Hypothesis: Past, Present, and Future. <i>Journal of Thrombosis and Thrombolysis</i> , 1998 , 5, 101-112 | 5.1 | 1 |
| 12 | Coronary artery injection technique: a quantitative in vivo investigation using modern catheters. <i>Catheterization and Cardiovascular Diagnosis</i> , 1998 , 44, 34-9 | | 5 |
| 11 | TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. <i>Circulation</i> , 1998 , 98, 2805-14 | 16.7 | 254 |
| 10 | TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. <i>Circulation</i> , 1997 , 95, 351-6 | 16.7 | 176 |
| 9 | Techniques in the Angiographic Analysis of Coronary Flow: Past, Present, and Future. <i>Journal of Interventional Cardiology</i> , 1996 , 9, 429-444 | 1.8 | 16 |
| 8 | TIMI frame count: a quantitative method of assessing coronary artery flow. <i>Circulation</i> , 1996 , 93, 879-88 | 16.7 | 1226 |
| 7 | Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. <i>Journal of the American College of Cardiology</i> , 1995 , 25, 582-9 | 15.1 | 55 |
| 6 | Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group. <i>Journal of the American College of Cardiology</i> , 1995 , 25, 1492-8 | 15.1 | 181 |
| 5 | The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Harvard Atherosclerosis Reversibility Project Research Group. <i>American Journal of Cardiology</i> , 1995 , 76, 78C-85C | 3 | 28 |
| 4 | Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning?. <i>Circulation</i> , 1995 , 91, 37-45 | 16.7 | 376 |
| 3 | Complications and long-term outcome after percutaneous coronary angioplasty in chronic hemodialysis patients. <i>American Heart Journal</i> , 1994 , 128, 252-5 | 4.9 | 85 |

2 Natural history of coronary atherosclerosis using quantitative angiography in men, and implications
for clinical trials of coronary regression. The Harvard Atherosclerosis Reversibility Project Study
Group. *American Journal of Cardiology*, **1993**, 71, 766-72 3 32

1 Acute ST Segment Elevation Myocardial Infarction216-239